Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
This study has been completed.
Information provided by:
First received: September 12, 2005
Last updated: October 31, 2013
Last verified: October 2013
The primary objective of this study is to compare the effectiveness of telmisartan 80 mg / hydrochlorothiazide 25 mg [Micardis HCT] to valsartan 160 mg / hydrochlorothiazide 25 mg [Diovan HCT] and placebo in the treatment of Stage 1 and Stage 2 hypertension.
Drug: telmisartan 80 mg / hydrochlorothiazide 25 mg
Drug: valsartan 160 mg / hydrochlorothiazide 25 mg
||Intervention Model: Parallel Assignment
Primary Purpose: Treatment
||A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Primary Outcome Measures:
- Mean seated trough cuff DBP and SBP [ Time Frame: after 8 week ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- The percentage of patients responding to treatment based on in-clinic mean seated trough cuff measurements [ Time Frame: after 8 week ] [ Designated as safety issue: No ]
- The percentage of patients with uncontrolled hypertension [ Time Frame: after 8 weeks ] [ Designated as safety issue: No ]
- Change in the in-clinic mean seated cuff DBP and SBP at the one and three hour post dose time points [ Time Frame: after 8 weeks ] [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||July 2006 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Ability to provide written informed consent.
- Age 18 years or older
- Ability to stop current antihypertensive therapy without unacceptable risk to the patient (investigator's discretion)
- Seated cuff DBP of ? 95 mmHg at Visit 2 (baseline)
Pre-menopausal women (last menstruation ? 1 year prior to start of run-in period) who:
- are not surgically sterile and/or
- are nursing or pregnant
- are of child-bearing potential and are NOT practicing acceptable means of birth control, do NOT plan to continue using this method throughout the study and do NOT agree to submit to periodic pregnancy testing during participation in studies of > 3-months duration. Acceptable methods of birth control include oral, implantable, transdermal, or injectable contraceptives, and Intra-Uterine Device (IUD).
- Known or suspected secondary hypertension.
- Mean seated SBP >= 180 mmHg or mean seated DBP >= 120 mmHg during any clinic visit prior to randomization.
Hepatic and/or renal dysfunction as defined by the following laboratory parameters:
- SGPT (ALT) or SGOT (AST) > 2 times the upper limit of normal range, or
- Serum creatinine > 3.0 mg/dL or creatinine clearance < 0.6 ml/sec.
- Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant or with only one kidney.
- Clinically relevant hypokalemia or hyperkalemia.
- Uncorrected volume depletion.
- Uncorrected sodium depletion.
- Primary aldosteronism.
- Hereditary fructose intolerance.
- Biliary obstructive disorders, cholestatis or moderate to severe hepatic in sufficiency.
- Patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists.
- History of drug or alcohol dependency within six months prior to start of run-in period.
- Chronic administration of any medications known to affect blood pressure, exc
Please refer to this study by its ClinicalTrials.gov identifier: NCT00168779
No publications provided
||Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
History of Changes
|Other Study ID Numbers:
|Study First Received:
||September 12, 2005
||October 31, 2013
||United States: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on April 17, 2014
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors